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The Epstein-Barr virus (EBV)-encoded LMP1 protein is an important component of the process of trans-
formation by EBV. LMP1 is essential for transformation of B lymphocytes, most likely because of its profound
effects on cellular gene expression. Although LMP1 is expressed in the majority of nasopharyngeal carcinoma
(NPC) tumors, the effect of LMP1 on cellular gene expression and its contribution to the development of
malignancy in epithelial cells is largely unknown. In this study the effects of LMP1 on the expression and
tyrosine kinase activity of the epidermal growth factor receptor (EGFR) were investigated in C33A human
epithelial cells. Stable or transient expression of LMP1 in C33A cells increased expression of the EGFR at both
the protein and mRNA levels. In contrast, expression of the EGFR was not induced by LMP1 in EBV-infected
B lymphocytes. Stimulation of LMP1-expressing C33A cells with epidermal growth factor (EGF) caused rapid
tyrosine phosphorylation of the EGFR (pp170) as well as several other proteins, including pp120, pp85, pp75,
and pp55, indicating that the EGFR induced by LMP1 is functional. LMP1 also induced expression of the A20
gene in C33A epithelial cells. In C33A cells, LMP1 expression increased the proliferative response to EGF, as
LMP1-expressing C33A cells continued to increase in number when plated in serum-free media supplemented
with EGF, while the neo control cells exhibited very low levels of viability and did not proliferate. Immunoblot
analysis of protein extracts from nude mouse-passaged NPC tumors also demonstrated that the EGFR is
overexpressed in primary NPC tumors as well as those passaged in nude mice. This study suggests that the
alteration in the growth patterns of C33A cells expressing LMP1 is a result of increased proliferative signals
due to enhanced EGFR expression, as well as protection from cell death due to LMP1-induced A20 expression.
The induction of EGFR and A20 by LMP1 may be an important component of EBV infection in epithelial cells
and could contribute to the development of epithelial malignancies such as NPC.
Epstein-Barr virus (EBV), a ubiquitious human herpesvirus,
is consistently detected in several human malignancies, includ-
ing endemic Burkitt’s lymphoma (BL), nasopharyngeal carci-
noma (NPC), and posttransplant lymphoma (32, 38, 46, 63).
EBV readily infects and transforms human B lymphocytes in
culture; however, the lack of a suitable epithelial cell infection
system has hindered studies of the mechanisms leading to
transformation of this cell type by EBV. Transformation of B
lymphocytes in vitro requires expression of four nuclear anti-
gens (EBNA1, -2, -3A, and -3C) as well as the latent mem-
brane protein 1 (LMP1) (8, 30, 56).
Analysis of EBV gene expression in biopsies of the human
epithelial malignancy NPC has revealed that viral gene expres-
sion is limited to EBNA1, LMP1, LMP2, and a family of
rightward transcripts from the BamHI A region of the EBV
genome (4, 17, 18, 25). The latent origin binding protein
EBNA1 has been detected in 100% of tumor biopsies, while
the LMP1 protein has been detected in approximately 60% of
tumor biopsies (14, 64). Analysis of carcinoma in situ or pre-
invasive lesions of the nasopharynx has revealed expression of
LMP1 protein in 100% of the cases, suggesting an important
role for LMP1 in the development of NPC (47).
Biochemical studies of the effect of LMP1 expression in B
lymphocytes have shown that LMP1 induces the expression of
the Ca21/calmodulin-dependent protein kinase (CaM kinase-
Gr), the B-cell activation antigen CD23, and adhesion mole-
cules ICAM-1, LFA-1, and LFA-3 as well as several molecules
with antiapoptotic properties, including A20 and bcl-2 (24, 34,
41, 61). The requirement for LMP1 expression in the transfor-
mation of B lymphocytes likely involves an effect on these
molecules. LMP1 also has transforming properties in rodent
fibroblasts, indicating that it can induce cellular changes in cell
types other than lymphocytes (1, 39, 60). Several studies have
suggested that LMP1 can also affect growth and differentiation
of immortalized, nontumorigenic epithelial cells in vitro, but
they did not reveal how these changes in growth control may be
mediated (9, 15).
The epidermal growth factor receptor (EGFR) is a mem-
brane-bound glycoprotein with an extracellular ligand binding
domain and an intracellular cytoplasmic domain which upon
binding of epidermal growth factor (EGF) possesses an acti-
vated intrinsic tyrosine kinase domain (6, 12, 57). Stimulation
of EGFR tyrosine kinase activity produces receptor autophos-
phorylation, which mediates interaction with SH2 and SH3
binding proteins. This in turn results in transcription factor
activation and DNA replication (44). An important pathway
activated by the EGFR tyrosine kinase is the Ras pathway,
mediated by the SH2-containing Shc and Grb2 proteins, which
through interaction with guanine nucleotide exchange factors
results in activation of Ras by increasing the level of bound
GTP (2, 3).
Increased expression of the EGFR gene is often associated
with transformation of cells of epithelial origin, and a myriad
of human epithelial tumors, including NPC, overexpress the
EGFR (52, 65). Immunohistochemical analysis of tissue from
these tumors in comparison to surrounding normal tissue dem-
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onstrated an elevated level of the EGFR protein in the tumor
tissue. Since EBV is an important factor in the development of
NPC, it was important to determine whether a viral gene prod-
uct induced expression of the EGFR, leading to a deregulation
of cellular growth control. The effect of LMP1 expression in
rodent fibroblasts or human squamous carcinoma cells resem-
bles that of activated Ras molecules, suggesting a common
biochemical pathway for these oncoproteins (9, 60). Since
overexpression or activation of the EGFR by LMP1 could
mimic an activated Ras pathway, LMP1 may exert its trans-
forming effects in epithelial cells through deregulation of the
EGFR.
In this study, the EBV-encoded LMP1 gene was expressed in
several established epithelial cell lines. The data indicate that
LMP1 induces expression of the EGFR at both the protein and
mRNA levels in the cervical carcinoma cell line C33A. Expres-
sion of LMP1 in C33A epithelial cells also resulted in increased
expression of the A20 gene, which has been shown to block
apoptosis in experimental systems (42). When the LMP1-trans-
fected cells were grown in serum-free media supplemented
with EGF, the cells exhibited increased viability, suggesting
that the LMP1 derivatives had a growth advantage over the
control cells. These results suggest that LMP1 may exert its
transforming properties in epithelial cells in part through the
increased expression of the cellular EGFR and A20 onco-
genes.
MATERIALS AND METHODS
Cell lines and NPC tumors. C33A and SiHa epithelial cells derived from
human cervical carcinomas were grown at 378C in Dulbecco’s modified Eagle’s
medium (DMEM-H) supplemented with 10% fetal calf serum (Irvine Scientific)
and antibiotics. HT29 cells derived from a colonic carcinoma and the cervical
carcinoma-derived ME-180 cell line were grown as described above except with
McCoys 5A medium. Cells were routinely grown in 100-mm-diameter cell culture
dishes and split 1:5 three times weekly. Lymphoid cell lines were maintained in
suspension at between 2 3 105 and 1 3 106 cells per ml in RPMI 1640 supple-
mented with 10% fetal calf serum and antibiotics. C33A cells expressing LMP1
were obtained by selection in 600 mg of G418 (Gibco) per ml following electro-
poration of an expression construct containing the LMP1 gene (B95-8 origin)
driven by a human K14 promoter (LMP1 clones 1C1, 2C, and 1B4 and pools P4,
P5, and P6) (27). The pGEM-based plasmid also contains the Neor cassette from
pMAMneo (Clontech). neo control cell lines were derived either with the
pMAMneo plasmid (neo pools P1, P2, and P3) or with the same construct from
which the promoter and LMP1 sequences were removed by restriction digestion
(neo clones 1C, 1B, and 1A2). ME-180 and HT29 cells expressing the LMP1
gene and relevant controls were constructed as described above. C15 and C17 are
EBV-positive NPC tumors which have been passaged serially in nude mice.
Immunoblot analysis of protein levels. Protein extracts were made by directly
scraping cells from tissue culture dishes at ;80% confluence into radioimmu-
noprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 1% deoxycholate
with protease inhibitors) with SDS sample buffer (C33A cells) or by resuspending
106 cells in phosphate-buffered saline (PBS) before adding equal volumes of 23
SDS sample buffer (lymphoid cells). EGFR expression in NPC tumors was
analyzed by using crude membrane preparations. Tumors were harvested from
nude mice, disrupted in a microdismembrator, and subjected to Dounce homog-
enization. Unlysed cells and nuclei were removed by low-speed centrifugation,
and crude membranes were pelleted at high speed. Protein (100 mg) from crude
membranes was suspended in PBS and SDS sample buffer. Extracts were boiled
for 10 min, separated on SDS–7% polyacrylamide gels, and transferred to sup-
ported nitrocellulose filters (Schleicher and Schuell) by using a Hoefer Semi-Dry
transfer apparatus. Filters were stained with Ponceau S stain to ensure equal
loading of protein in all lanes. Nonspecific reactivity was blocked by incubation
overnight in Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat dried
milk (BLOTTO). Supernatant from the S12 monoclonal antibody (a generous
gift of David A. Thorley-Lawson) was used at a 1:10 dilution in BLOTTO for
the detection of LMP1. A rabbit antiserum raised against the carboxy-terminal
100 amino acids of the EGFR fused to glutathione S-transferase (ERCT) was
used at a 1:1,500 dilution in BLOTTO for the detection of the EGFR. The
anti-phosphotyrosine PT-66 antibody (Sigma) was used at a 1:2,000 dilution in
BLOTTO for the detection of phosphotyrosine-containing proteins. Appropriate
secondary anti-mouse or anti-rabbit antibodies (Amersham) were used at a
dilution of 1:2,000 in BLOTTO to detect bound primary antibody. Reactive
proteins were detected by incubation of washed filters in the enhanced chemi-
luminescence system (ECL; Amersham) followed by exposure to autoradio-
graphic film.
Analysis of EGFR upregulation in a transient assay. C33A cells were
trypsinized at subconfluence, counted, and resuspended in DMEM-H at a con-
centration of 107 cells per 0.5 ml of medium. Cells (107) were electroporated at
1,500 V by using a Zapper (U.W. Medical Electronics), resuspended in 10 ml of
DMEM-H, and plated in 100-mm-diameter cell culture dishes. Typically 10 mg of
DNA was transfected per condition. The pSV2(gpt)-LMP1 and pSV2(gpt) plas-
mids were used for expression of LMP1 and for relevant controls (60). A total of
2 mg of each pSV2 plasmid was suspended with 8 mg of calf thymus DNA as a
carrier, and each suspension (including 10 mg of calf thymus DNA alone) was
electroporated into 107 cells. Cells were harvested 48 h after transfection directly
into RIPA buffer containing SDS loading buffer and analyzed by immunoblotting
for EGFR and LMP1 expression as described above.
Tyrosine phosphorylation and immunoprecipitation of the EGFR. C33A de-
rivatives were cultured overnight in serum-free media to minimize background
tyrosine phosphorylation due to growth factors in serum. Cells were then incu-
bated for various times in serum-free media supplemented with 20 mM HEPES
(N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; pH 7.4) and 500 ng of
recombinant EGF (Austral Biologicals) per ml. Cells were lysed directly in RIPA
buffer and then diluted into SDS sample buffer. Samples were subsequently
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) for phosphoty-
rosine-containing proteins as described above. For immunoprecipitation of the
EGFR, cells were treated for 2 min with EGF as described above, washed in PBS
containing 100 mM Na3VO4, lysed in lysis buffer (25 mM Tris [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 1 mM dithiothreitol, 1% Nonidet P-40, 10 mM NaF, 100
mM Na3VO4), and centrifuged for 15 min at 48C, to pellet cellular debris. The
EGFR was precipitated from the resulting supernatant with the anti-ERCT
rabbit antiserum, and immune complexes were pelleted with Pansorban (Calbio-
chem), washed twice in lysis buffer, and analyzed by SDS-PAGE. Immunoblots
were analyzed for the EGFR and phosphotyrosine proteins as described above.
RNA isolation and Northern (RNA) blot analysis. Total cellular RNA was
isolated by directly lysing cells in guanidine isothiocyanate (GITC), layered over
CsCl, and centrifuged for 24 h in an ultracentrifuge. The GITC and CsCl were
carefully removed, and the resulting pellet was resuspended in diethyl pyrocar-
bonate (DEPC)-treated H2O. Northern blots were prepared with poly(A)1RNA
isolated by using Oligotex-dT beads according to the manufacturer’s instructions
(Qiagen) or with total cellular RNA. Northern blots were baked in a vacuum
oven for 2 h, prehybridized for .2 h (in a buffer containing 63 SSPE [13 SSPE
is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA {pH 7.7}], 103 Denhardt’s
solution, 0.5% SDS, and 50 mg of denatured DNA per ml), and hybridized
overnight in the same buffer at.106 cpm/ml with random primed probes labeled
according to the manufacturer’s specifications (Promega, Madison, Wis.). The
EGFR 64.3, CD23, and b-actin and A20 cDNAs used as probes were kindly
provided by J. Schlessinger, E. Kieff, and S. Haskill, respectively.
Reverse transcription-based PCR (RT-PCR) analysis. RNA was extracted as
described above from the C33A derivatives, as well as the EGFR-positive HT29
and SiHa cell lines. cDNA was synthesized from 5 mg of total cellular RNA by
priming with oligo(dT) and reverse transcribed according to the manufacturer’s
specifications (Boehringer Mannheim). cDNA corresponding to 0.5 mg of RNA
was amplified for 30 cycles in the PCR. Amplifications without reverse transcrip-
tion were included to ensure amplification of mRNA. Each cDNA preparation
was amplified with actin-specific primers to ensure the integrity of the cDNA.
EGFR amplification was performed with primers specific for the membrane-
bound full-length EGFR (ER10, positions 1813 to 1833, and ER9, positions 2260
to 2280 of the EGFR cDNA) (37). PCR products were subjected to electro-
phoresis through 1% agarose, and products were visualized by ethidium bromide
staining. For analysis of EGFR expression, PCR products were transferred to
supported nitrocellulose and filters were hybridized overnight with an end-la-
beled internal oligonucleotide (ER1, positions 2057 to 2077 of EGFR cDNA)
prepared according to the manufacturer’s specifications (NEB) (37). In some
cases blots were analyzed on a Phosphorimaging screen (Molecular Dynamics).
Stability of EGFR mRNA. mRNA stabilization experiments were carried out
by treating 80% confluent cultures with fresh media containing 20 mg of actino-
mycin D per ml. RNA was isolated at various times posttreatment (0 to 24 h) and
analyzed by RT-PCR as described above. Twenty cycles of PCR were performed
to keep the PCR at a subplateau level, and gels were transferred to supported
nitrocellulose and hybridized with the ER1 probe.
Growth curves of C33A derivatives expressing LMP1. For analysis of the
growth characteristics of LMP1-expressing C33A cells and neo controls, cells
were trypsinized, pelleted, and washed in serum-free media. Cells were resus-
pended and plated in duplicate at a density of 53 105 cells per tissue culture dish
in serum-free media supplemented with 25 ng of EGF per ml. On subsequent
days following plating cells were scraped from the dishes and the number of
viable cells was assessed by trypan blue exclusion.
RESULTS
Stable expression of LMP1 in human epithelial cells in-
duces EGFR expression. To determine the effect of the EBV-
encoded latent membrane protein 1 (LMP1) on the EGFR,
VOL. 69, 1995 LMP1 INDUCES EXPRESSION OF EGFR 4391
several human epithelial cell lines were transfected with the
LMP1 gene under the control of the human keratin 14 (K14)
promoter (27). The LMP1-expressing and neo control cell lines
derived from the human cervical carcinoma C33A were ana-
lyzed by immunoblotting for EGFR (170 kDa) and LMP1 (63
kDa) expression (Fig. 1). Little or no EGFR expression was
detected in the parental cell line C33A or in neo control sub-
clones; however, expression of LMP1 caused a dramatic in-
crease in the level of the EGFR protein. Six cell lines express-
ing LMP1 were analyzed (three subclones and three pools
established from .50 colonies), and although there were dif-
ferences in the expression of both LMP1 and the EGFR be-
tween different cell lines, there was a clear correlation between
LMP1 expression and expression of the EGFR in all cell lines
tested.
In order to further characterize the effect of LMP1 on
EGFR expression, two additional cell lines, HT29 colonic car-
cinoma cells and ME-180 cervical carcinoma cells were stud-
ied. Both of these cell lines express relatively high levels of the
EGFR which were unaffected by expression of LMP1 (data not
shown). These experiments indicate that LMP1 is able to in-
duce expression of the EGFR in human epithelial cells lacking
detectable EGFR but that it did not significantly alter EGFR
expression in several cell lines expressing the EGFR.
Induction of the EGFR by LMP1 in a transient assay. LMP1
has been shown to exert toxic effects when expressed at high
levels in several cell types (1, 23, 39). To eliminate the possi-
bility that overexpression of the EGFR resulted from an indi-
rect mechanism to overcome the toxic effect of LMP1 in es-
tablished cell lines, the effect of LMP1 on EGFR expression
was determined in a transient assay. C33A cells were trans-
fected with the pSV2(gpt) and pSV2(gpt)-LMP1 vectors,
which contain the human metallothionein promoter and cap-
ping site driving the expression of LMP1 (60). Cells were
harvested 48 h after transfection and analyzed by immunob-
lotting for LMP1 and EGFR expression (Fig. 2). As in the
previous experiments with LMP1-derived cell lines, both the
parental cells and cells transfected with the control pSV2(gpt)
vector exhibited little or no EGFR expression. In contrast, cells
transfected with the pSV2(gpt)-LMP1 vector expressed con-
siderable levels of both the LMP1 and EGFR gene products.
These results confirm the previous finding that expression of
LMP1 was directly responsible for the increased EGFR ex-
pression and that this increased expression was not due to
secondary changes occurring in long-term cultures brought
about by LMP1 expression.
EGFR expression in EBV-infected lymphocytes. Since EBV
infects both epithelial cells and B lymphocytes in vivo, the
effect of LMP1 expression on the EGFR was investigated in
B-lymphocyte cell lines. Expression of the EGFR is normally
restricted to cells of epithelial and mesenchymal origin, and
this expression is not normally detected in hematopoietic cells,
FIG. 1. Induction of EGFR protein in C33A epithelial cells. (A) Immunoblot analysis of C33A subclones transfected with the K14-LMP1 expression construct or
the neo control construct. The blots were probed with an anti-EGFR rabbit antiserum or with the anti-LMP1 monoclonal antibody S12. The locations of the 170-kDa
EGFR and 63-kDa LMP1 proteins as well as the migration of molecular mass markers are indicated. 1C and 1A2 are subclones which contain the neo control vector,
while 1C1, 2C, and 1B4 are LMP1-expressing subclones. Parent represents untransfected C33A cells. (B) Similar analysis of LMP1 and neo cell lines generated by
pooling .50 neomycin-resistant colonies. P1 to P3 are neo cell lines, while P4 to P6 are LMP1-expressing cell lines. kd, kilodaltons.
FIG. 2. Induction of EGFR expression through transient expression of
LMP1 in C33A cells. Cells (107) were transfected with 2 mg of either the LMP1
expression plasmid pSV2(gpt)-LMP1 or the control pSV2(gpt) plasmid along
with 8 mg of carrier DNA. As an additional control 10 mg of carrier DNA alone
was transfected. At 48 h after transfection, cells were harvested and analyzed by
immunoblot analysis for the 170-kDa EGFR and 63-kDa LMP1 proteins as
described in the legend to Fig. 1. kd, kilodaltons.
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including B lymphocytes. Although the EGFR could be readily
detected in the C33A cells expressing LMP1, expression of the
EGFR was not detected by immunoblot analysis in any of the
lymphocyte cell lines (Fig. 3). The cell lines examined included
the EBV-infected marmoset and human lymphoid cell lines
B95-8 and CB5 and the BL cell line Raji. These cell lines all
express significant levels of the LMP1 protein. Additionally,
EGFR expression was not detected in the EBV-infected, de-
fective BL cell line P3-HR-1, the EBV-negative BL Louckes
cell line, or the T-cell leukemia Jurkat cell line. Thus, expres-
sion of the EGFR is not likely to be important in lym-
phomagenesis, regardless of the status of EBV. These results
also indicated that expression of LMP1 has distinct effects on
cellular gene expression in epithelial and lymphoid cells.
Expression of the EGFR in EBV-infected NPC tissue. The in
vitro experiments indicated that the EBV-encoded LMP1 gene
is capable of inducing expression of the EGFR in established
human epithelial cells. EBV is strongly associated with the
human epithelial cell malignancy NPC. Thus, it is likely that
LMP1 is an important factor in the events leading to tumor
formation. The expression of the EGFR in several NPC tu-
mors, including the C15 and C17 tumors passaged in nude
mice, as well as an NPC sample (AL) which was obtained at
autopsy, was examined. Crude membrane fractions were pre-
pared from each tumor, and 100 mg of protein from each
sample was subjected to SDS-PAGE with equal loadings dem-
onstrated by Coomassie blue staining (data not shown). Im-
munoblot analysis using the EGFR-specific anti-ERCT rabbit
antiserum demonstrated high-level expression of the EGFR in
the two nude-mouse-passaged NPC tumors compared with
control mouse liver tissue (Fig. 4). The AL sample contained
intermediate levels of the EGFR, which could be an underes-
timate of the total EGFR level in this tumor since NPC sam-
ples normally contain significant levels of infiltrating lympho-
cytes not found in nude-mouse-passaged NPC samples.
Expression of LMP1 was detected in each of the NPC samples
analyzed (14, 50, 51, 64). The upregulation of the EGFR in
human epithelial cell lines in vitro by LMP1 and the expression
of the EGFR in NPC suggest that LMP1 may contribute to the
development of NPC in part through induction of the EGFR.
Ligand-dependent activation of EGFR tyrosine kinase in
LMP1-expressing C33A cells. Stimulation of cell lines express-
ing the EGFR with EGF normally results in a rapid and tran-
sient activation of the EGFR tyrosine kinase. In order to de-
termine if the EGFR upregulated by LMP1 in C33A cells is a
functional tyrosine kinase, LMP1-converted C33A cells and
neo control C33A cells were treated with 500 ng of EGF per ml
for 2 min and the EGFR was immunoprecipitated with the
anti-ERCT antiserum. Immunoprecipitates were subjected to
SDS-PAGE and analyzed by immunoblotting for either total
EGFR (Fig. 5A, anti-ERCT) or tyrosine-phosphorylated
EGFR by using anti-phosphotyrosine antibodies (Fig. 5B, anti-
PY). As expected, the EGFR was detected only in the C33A
cells expressing LMP1. The anti-ERCT antibody detects both
phosphorylated and unphosphorylated EGFR; therefore, the
EGFR was detected in immunoprecipitates from treated and
untreated cells (Fig. 5A). Upon treatment with EGF, the
EGFR in the LMP1-expressing cells was phosphorylated on
tyrosine as evidenced by its reactivity with the anti-phosphoty-
rosine antibody (Fig. 5B). Tyrosine phosphorylation was not
detected in the neo control C33A cells, or in the untreated
LMP1-expressing C33A cells. These data indicate that the
EGFR upregulated by LMP1 is functional and capable of
stimulation by the mitogen EGF.
Induction of EGFR tyrosine kinase activity is known to
initiate tyrosine phosphorylation of several substrate proteins
which ultimately lead to altered gene expression and DNA
synthesis. To determine the pattern of tyrosine-phosphorylated
proteins in C33A epithelial cells, neo control and LMP1-ex-
pressing cells were stimulated with EGF and whole-cell lysates
were subjected to immunoblot analysis with anti-phosphoty-
rosine antibodies (Fig. 5C). Cells were treated with EGF and
harvested at various time points following stimulation. As ex-
pected, the 170-kDa EGFR was rapidly phosphorylated on
tyrosine in cells expressing LMP1, while phosphorylation was
not detected in the neo control cells. Additional proteins, in-
cluding pp120, pp85, pp75, and pp55, were also phosphory-
lated on tyrosine in the LMP1 expressing cells. Phosphoryla-
tion of these additional proteins was dependent both on EGF
and on the EGFR, as phosphorylation of these proteins was
not detected in the non-EGFR-expressing neo control cells
treated with EGF. Tyrosine phosphorylation in the LMP1-
expressing cells was analyzed at later time points to determine
the time course of dephosphorylation. The EGFR and sub-
strate proteins remained tyrosine phosphorylated up to 30 min
following stimulation with EGF, although the levels of phos-
phorylation gradually decreased with time (Fig. 5C). Examina-
FIG. 3. LMP1 expression in B lymphocytes does not alter EGFR expression.
Extracts from 5 3 105 cells were analyzed for EGFR and LMP1 expression as
described in the legend to Fig. 1. B95-8 is an EBV-infected marmoset cell line,
and CB5 is a human lymphoblastoid cell line established with B95-8 virus. Jurkat
and Louckes are EBV-negative T- and B-cell lymphomas, respectively. P3-HR-1
is a subclone of a BL cell line which does not express LMP1. Raji is an LMP1-
expressing BL cell line. C33-LMP1 is a subclone of C33A epithelial cells that
expresses LMP1. The locations of the 170-kDa EGFR and 63-kDa LMP1 pro-
teins as well as the migration of molecular mass markers are indicated. kd,
kilodaltons.
FIG. 4. LMP1 expression in NPC tumor samples. Immunoblots containing
100 mg of membrane proteins extracted from NPC samples were analyzed for
EGFR expression as described in the legend to Fig. 1. B95-8 is an EBV-positive
marmoset B-cell line. Mouse liver is normal mouse liver tissue obtained at biopsy
from a mouse harboring a C15 tumor. AL is an NPC metastasis of the liver and
was obtained at autopsy. C15 and C17 are nude-mouse-passaged NPC tumors.
kd, kilodaltons.
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tion of tyrosine phosphorylation patterns in LMP1-expressing
ME-180 cells, which express the EGFR in the absence of
LMP1, revealed similar levels of tyrosine-phosphorylated pro-
teins whose dephosphorylation exhibited a time course similar
to that of proteins in the neo control ME-180 cells (data not
shown). These data indicate that LMP1 does not significantly
alter the rate of downregulation by affecting internalization,
dephosphorylation, or degradation of the EGFR.
Induction of EGFR mRNA levels by LMP1. To determine if
the increased level of EGFR protein detected in LMP1-ex-
pressing C33A cells was due to an increased mRNA level, the
expression of the EGFR mRNA was analyzed by Northern
blotting. Samples of poly(A)1 RNA from LMP1-expressing
cells, neo controls, and C33A parental cells were hybridized
with the 64.3 cDNA probe encompassing 768 bp of the EGFR
open reading frame 39 to the putative transmembrane domain
(57). The HT29 cell line, which expresses the EGFR, was
included as a positive control. Hybridization was not detected
in the parental C33A cells, while mRNAs of 10.5 and 5.8 kb
were detected in the LMP1-expressing cells and the HT29 cells
with the 64.3 cDNA probe (Fig. 6A). The 10.5- and 5.8-kb
mRNA species were also detected in RNA preparations from
the C15 NPC tumor, which expresses the EGFR protein, and
were identical in size to the mRNAs detected in other cell
types expressing the EGFR (Fig. 4 and data not shown) (11,
57). The 10.5- and 5.8-kb EGFR mRNAs both initiate in the
same promoter region and differ in the 39 untranslated region
(31). The Northern blot was reprobed with a cDNA probe for
b-actin to ensure equal loading of the mRNAs (Fig. 6B).
Expression of the EGFR was also analyzed by RT-PCR
(Fig. 6C). Amplifications were also performed on equivalent
amounts of cDNA from the EGFR-expressing HT29 and SiHa
epithelial cell lines. As expected, the LMP1-expressing sub-
clones 1C1 and 2C contained elevated levels of EGFR tran-
scripts compared with the C33A parental cells and the 1C neo
control subclone. The 1C1 subclone expressed more EGFR
RNA than the 2C subclone, consistent with previous analysis of
EGFR levels as detected by Northern blot analysis of mRNA
and Western blot (immunoblot) analysis of total cellular pro-
tein. Low levels of EGFR transcription were detected by RT-
PCR in the parental cells and neo subclone 1C. These data
confirm the finding that LMP1 expression elevates EGFR
mRNA levels.
FIG. 5. Phosphotyrosine analysis of the EGFR and substrate proteins in
LMP1-converted C33A cells. LMP1 and control C33A cells were treated with
EGF for 2 min, and the EGFR was immunoprecipitated as described in Mate-
rials and Methods. Immunoprecipitates were analyzed by immunoblotting for
total EGFR with the anti-ERCT rabbit antiserum (A) or for tyrosine-phospho-
rylated EGFR with the anti-phosphotyrosine (anti-PY) antibody PT-66 (B). (C)
Tyrosine phosphorylation in whole-cell lysates as analyzed by immunoblotting
with the anti-PY antibody PT-66. LMP1-expressing and neo control cells were
treated with EGF for various times and analyzed for phosphotyrosine-containing
proteins. The blot is intentionally overexposed to visualize less-prominent bands
in the range of 55 to 85 kDa.
FIG. 6. Expression of EGFR-specific mRNAs in C33A cells expressing
LMP1. (A) Poly(A)1 RNA (15 mg) isolated from LMP1-expressing and control
subclones analyzed by Northern blotting for EGFR expression with the 64.3
EGFR cDNA probe. The 10.5- and 5.8-kb mRNA species are indicated. An
equal amount of RNA from the EGFR-expressing HT29 cell line was included
as a control. (B) The blot was reprobed with a b-actin cDNA to demonstrate
equal loading and integrity of the RNAs. (C) RT-PCR analysis of EGFR mRNA
in the C33A subclones. cDNA corresponding to 0.5 mg of RNA was amplified for
20 cycles of PCR as described in Materials and Methods. cDNA synthesis
without reverse transcription was performed to ensure amplification of RNA.
After electrophoresis through 1% agarose gels, PCR products were transferred
to nitrocellulose and probed with 32P-labeled ER1 oligonucleotide as described
in Materials and Methods. Equal amounts of cDNA from the EGFR-positive
HT29 and SiHa cell lines were included as controls.
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Stability of EGFR mRNA. In order to more precisely deter-
mine the mechanism leading to induction of steady-state levels
of EGFR mRNA, the effect of LMP1 expression on the sta-
bility of the EGFR message was investigated. Previous reports
have suggested that the accumulation of EGFR mRNA ex-
pression following EGF stimulation involved stabilization of
the EGFR message (28). C33A cells expressing LMP1 (1C1)
and the vector control (1C) were treated with 20 mg of acti-
nomycin D per ml at 80% confluence for 0 to 24 h, and RNA
was harvested at several times after treatment. Since EGFR
mRNA levels could be detected in the neo control cells only by
RNA PCR, this methodology was utilized to determine the
turnover of the EGFR mRNA in the two subclones. Determi-
nation of EGFR mRNA turnover in the 1C1 (LMP1 express-
ing) subclone by Northern and RNA PCR analysis gave similar
results, indicating that the RNA PCR analysis would be valid in
a determination of EGFR mRNA turnover (data not shown).
cDNA was subjected to 20 rounds of PCR amplification as
described above and hybridized with an internal oligonucleo-
tide corresponding to the EGFR sequence (Fig. 7). Quantita-
tion of the EGFR mRNA on a Phosphorimaging screen (Mo-
lecular Dynamics) indicated that the half-life of the mRNA
was approximately 12 h in both the LMP1-expressing and con-
trol subclones of C33A cells.
Analysis of the short-lived c-Fos mRNA levels demonstrated
that c-Fos mRNA was completely degraded by 3 h, confirming
the shutoff of transcription by actinomycin D in these cells
(data not shown). Previous analyses have indicated that the
half-life of the EGFR mRNA in epithelial cells is approxi-
mately 3 h, while the data presented here suggest that the
half-life of this mRNA may be significantly longer in some
epithelial cells (21, 28). These data indicate that LMP1 does
not alter the half-life of the EGFR message and suggest that
induction of EGFR transcription leads to the increased steady-
state levels of EGFR mRNA.
Expression of LMP1 in C33A epithelial cells induces A20
expression. LMP1 expression in B lymphocytes induces a num-
ber of cellular changes, including the upregulation of mRNA
levels of A20, bcl-2, and CD23 (FcεRIIb form) (24, 34, 61).
Induction of gene expression by LMP1 in lymphocytes is
thought to be responsible for cellular activation as well as
prevention of apoptosis. To investigate the expression of A20
in the C33A epithelial cells expressing LMP1, Northern blots
of total cellular RNA were hybridized with a cDNA probe
specific for the A20 gene (Fig. 8). C33A cells expressing LMP1,
P4 (LMP1) and P5 (LMP1), also expressed significant levels of
A20 mRNA, while the neo control cells, P1 (Neo) and P2
(Neo), did not have detectable levels of A20 mRNA. In, con-
trast CD23 and bcl-2 gene expression was not altered in the
C33A cells expressing LMP1 (data not shown). These data
indicate that LMP1 expression has differential effects on lym-
phocytes and epithelial cells, with A20 upregulation being
common to both cell types, CD23 and bcl-2 upregulation being
specific to lymphocytes, and EGFR upregulation being specific
to epithelial cells.
LMP1 expression alters the growth rates of C33A cells in
serum-free media. Single gene transfer experiments with the
EGFR have demonstrated that the EGFR can transform ro-
dent fibroblasts in vitro in a ligand-dependent manner (58).
The growth pattern of LMP1-expressing C33A cells was com-
pared with that of neo control C33A cells in serum-free media
supplemented with 25 ng of EGF (Austral Biologicals) per ml.
Cells (53 105) were seeded in fresh media, and viable cells (on
the basis of trypan blue exclusion) were counted at intervals
following plating in the serum-free media (Fig. 9). The data
presented are the results of three independent experiments
FIG. 7. Stability of the EGFR mRNA. C33A cells expressing LMP1 and
control cells were treated at 80% confluence with 20 mg of actinomycin D, and
RNA was isolated at various time points following treatment. cDNA was pre-
pared as described in Materials and Methods. After electrophoresis and transfer
to nitrocellulose, the blot was probed with 32P-labeled ER1 oligonucleotide and
analyzed with a Phosphorimaging screen (Molecular Dynamics).
FIG. 8. Expression of A20-specific mRNAs in C33A cells expressing LMP1.
Aliquots of RNA (40 mg) were isolated from LMP1-expressing (P4 and P5) and
neo control (P1 and P2) C33A cell lines and analyzed by Northern blotting with
the A20 cDNA probe. The locations of rRNAs and the 4.4-kb A20 mRNA are
indicated.
FIG. 9. Growth of LMP1-expressing C33A cells in serum-free media supple-
mented with EGF. Exponentially growing C33A LMP1-expressing cells and neo
control cells were harvested, washed once in serum-free media and seeded at a
density of 5 3 105 cells per plate in serum-free media supplemented with 25 ng
of recombinant EGF (Austral Biologicals) per ml. On various days after seeding,
the cells were harvested and cell viability was assessed on the basis of trypan blue
exclusion. The numbers and errors depicted in the graph represent three indi-
vidual experiments performed in duplicate.
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performed in duplicate. After an initial decrease in cell num-
ber, probably due to plating efficiency of the C33A cells in
serum-free media, the C33A cells expressing LMP1 increased
in numbers to much greater densities than the neo controls. At
day 6 following plating, the LMP1-expressing C33A cells had
increased in number to 8.8 3 106 cells per plate, while the neo
control cells had increased to only 1.8 3 106 cells per plate.
Following day 6, both populations of cells began to decrease in
viability, indicating that while short-term cultures of LMP1-
expressing C33A cells were able to grow in serum-free media,
LMP1 was unable to transform C33A cells to complete serum
independence. These data suggest that, in a manner similar to
that of its effects in lymphocytes, LMP1 induces alterations in
epithelial cells that influence cellular growth and differentia-
tion.
DISCUSSION
The EBV-encoded LMP1 protein is one of several proteins
essential for growth transformation of B lymphocytes in vitro,
and it is the only EBV-encoded protein shown to transform
rodent fibroblasts (1, 30, 60). The protein is expressed in EBV-
immortalized B lymphocytes and has also been detected in
approximately 65% of all NPC tumors (14, 64). The lack of a
suitable in vitro infection system has slowed the understanding
of the potential role of LMP1 in these tumors; however, sev-
eral studies using single gene transfer of LMP1 into epithelial
cells revealed that LMP1 affects epithelial cell growth and
differentiation. In the SCC12F squamous carcinoma cell line,
expression of LMP1 inhibited terminal differentiation of po-
larized cells grown on feeder layers, while LMP1 expression in
the immortalized RHEK keratinocyte cell line induced tumor-
igenicity in nude mice (9, 15). The underlying molecular events
that affect cellular growth and differentiation by LMP1 in ep-
ithelial cells are unknown.
The EGFR is a membrane-bound tyrosine kinase frequently
overexpressed in epithelial tumors (62). Ligand-dependent ac-
tivation of the EGFR has been shown to transform rodent
fibroblasts in vitro; however, the mechanisms leading to the
deregulation of EGFR in human tumors are not well under-
stood (31, 58). Increased levels of EGFR protein and mRNA
have been observed and amplification of the gene encoding the
EGFR has been detected in a number of cell lines derived
from epithelial tumors (33, 62). Regulation of EGFR expres-
sion, EGFR kinase activity, and the expression of aberrant
EGF receptors have also been shown to be associated with
viral oncogenesis. The avian erythroblastosis retrovirus en-
codes a truncated EGFR protein consisting of the transmem-
brane and tyrosine kinase domains of the cellular EGFR (13).
This truncated protein possesses a constitutively active tyrosine
kinase and efficiently transforms chicken embryo fibroblasts in
culture (16, 19). The E5 open reading frame of both bovine
papillomavirus and human papillomavirus prolongs the stimu-
lated tyrosine kinase activity of the EGFR, possibly because
of inhibition of EGFR degradation. This results in increased
levels of activated EGFR on the cell surface (35, 55). The
hepatitis B virus X-gene product increases EGFR levels when
expressed in human hepatoma-derived cells through upregu-
lation of the EGFR promoter, resulting in increased steady-
state levels of both EGFR mRNA and protein (36). These
studies suggest that altered regulation of the EGFR signal,
either by amplification or overexpression or in experimental
models through the action of viral oncogenes, may be an im-
portant step in the transformation of epithelial cells. The data
presented here reveal that the EBV-encoded LMP1 protein
also targets the EGFR in epithelial cells by upregulating the
steady-state expression of EGFR mRNA and protein.
Overexpression of the EGFR has also been shown to alter
the abilities of cell lines to form tumors in nude mice. Intro-
duction of a human EGFR expression construct into NIH 3T3
cells rendered the cells capable of forming tumors in nude
mice (58). In addition, alteration of the EGFR number in
MCF-7 and A431 human epithelial cell lines altered their tu-
mor forming capacity (53, 59). The MCF-7 breast epithelial
cell line, which expresses low levels of the EGFR, forms tu-
mors in vivo only in an estrogen-dependent manner. However,
selection of adriamycin-resistant MCF-7 cell lines, which over-
express the EGFR, allowed hormone-independent tumor for-
mation (59). Selection of A431 cells with decreased levels of
EGFR reduced tumor volume and slowed tumor growth, sug-
gesting the importance of EGFR overexpression in the forma-
tion of tumors in vivo (53). In this study, the accumulation of
the EGFR protein enabled the cells to grow to higher cell
densities when plated in serum-free media supplemented with
EGF. This suggests that LMP1-induced EGFR overexpression
influences cellular growth. The finding that the EGFR is also
overexpressed in NPC tissue suggests that upregulation of
EGFR expression may contribute to the development of NPC.
Analyses of tyrosine phosphorylation indicated that the
LMP1-induced EGFR is fully functional and is capable of
binding to EGF and becoming phosphorylated on tyrosine
residues. The additional proteins, including pp55, pp75, pp85,
and pp120, that became tyrosine phosphorylated after treat-
ment with EGF are similar to those detected in other epithelial
cells following stimulation of the EGFR with EGF (6, 10).
Previous studies of the EGFR suggest that the 55-kDa phos-
phoprotein in the EGF-stimulated C33A cells may be the Shc
protein. Shc has been shown to link the EGFR to the Ras
pathway through interaction with Grb2 (2, 45, 49). Since it has
been suggested that LMP1 can mimic activated Ras in the
prevention of terminal differentiation of stratified epithelial
cell cultures, it is possible that LMP1 exerts this physiologic
effect in part by upregulating expression of the EGFR (9).
Activation of the EGFR in some cells leads to tyrosine phos-
phorylation of the 85-kDa regulatory subunit of the phospha-
tidylinositol 39-kinase (PI3-kinase). In this manner the EGFR
activates the phosphoinositol second messenger pathway (5,
26, 54). Interestingly, the interaction of polyomavirus middle T
antigen with phosphatidylinositol 39-kinase may be involved in
the transformation of 3T3 cells, as mutants of middle T that
failed to interact with phosphatidylinositol 39-kinase failed to
transform (5). Tyrosine phosphorylation of substrate proteins
in LMP1-transfected C33A cells suggests that activation of
signal transduction cascades resulting from LMP1 expression
may be important in epithelial cell proliferation and transfor-
mation. It will be particularly important to determine whether
LMP1 also enhances production of an EGFR ligand such as
transforming growth factor a, thereby setting up a self-stimu-
latory autocrine loop.
The analyses of EGFR expression indicate that the EGFR
induced by LMP1 is due to an increase in the steady-state level
of EGFR mRNA. Overexpression of EGFR mRNA in human
tumor cell lines has been shown to involve mRNA stabiliza-
tion, promoter activation, and relief of transcription termina-
tion signals in intron 1 of the EGFR gene (7, 11, 20, 21, 28).
The stability of the EGFR mRNA was not affected by LMP1,
suggesting that LMP1 activates EGFR transcription. Experi-
ments with lymphocytes have indicated that LMP1 may at least
in part activate transcription through induction of the NF-kB
transcription factor (22, 34, 48). The EGFR promoter se-
quences that have been previously analyzed contain 1.3 kb 59 to
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the transcription initiation site and do not contain any identi-
fiable NF-kB binding sites (29). The activity of the EGFR
promoter-CAT recorder constructs in C33A and ME-180 cells
was discordant with the level of endogenous EGFR expression,
and the promoter constructs were not activated by LMP1 (data
not shown). Previous studies have suggested the presence of
important regulatory sequences in intron 1 of the EGFR gene.
The direct induction of EGFRmRNA by LMP1 will enable the
identification of important regulatory sequences for EGFR
transcription and potentially lead to the identification of addi-
tional transcriptional pathways that are activated by LMP1.
As in B lymphocytes, LMP1 upregulated expression of the
A20 gene in the C33A epithelial cells. The A20 promoter has
been cloned and was shown to be induced through the activa-
tion of NF-kB by LMP1 (34). Expression of LMP1 in C33A
epithelial cells does activate NF-kB family members, and so it
is likely that upregulation of A20 gene expression in C33A cells
is a result of NF-kB activation (43). The expression of other
NF-kB-inducible proteins and their influence on epithelial cell
growth are likely to be important in the formation of NPC.
A20 expression has been shown to protect cells from tumor
necrosis factor alpha induced apoptosis (42). Interestingly,
LMP1 has recently been shown to engage signaling proteins for
the tumor necrosis factor family receptors (40). Activation of
these signaling molecules by LMP1 could mimic ligand binding
to this family of receptors, and therefore subsequent induction
of A20 may be important for the protection of apoptosis in-
duced by activation of this pathway.
This is the first identification of upregulation of a cellular
tyrosine kinase by the EBV-encoded LMP1 gene. The EGFR
induced by LMP1 is a fully functional tyrosine kinase that
appears to activate signal transduction cascades important in
cellular proliferation. In addition, increased growth of LMP1-
converted C33A cells in serum-free media may reflect the
enhanced proliferation effected by the EGFR and possibly the
inhibition of apoptosis by the A20 molecules. The upregulation
of a biologically active EGFR molecule may represent an im-
portant contribution by LMP1 to the formation of epithelial-
cell-derived tumors like NPC.
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